Frontierby eninvs

Language: EN / RU

Aspen PharmacareUSD

– The company sells medicines in multiple markets through its commercial pharmaceuticals business, whose products include anaesthetics. Its manufacturing division produces pharmaceuticals and ingredients for the group and for third-party customers, including sterile products.

At a glance: strengths & risks
✓Turned profitable (FY)✓Net cash balance sheet✗Revenue declining (-20%)✗Margins compressing (25%→8%)

ZA_APN

Price chart

178.15 ZARDay -0.57%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
178.15 ZAR · -0.57%
Market cap
4.4 bn USD

Growth

Δ revenue y/y
-24.8%
Δ EBITDA y/y
-101.5%

Multiples

P/E (LTM)
27.8x
P/B (FY)
0.9x
P/E (ann.)
30.5x
EV/EBITDA (LTM)
28.0x
EV/EBITDA (ann.)
<0

Cash return

Dividend yield
1.3%
FCF yield (LTM)
6.4%

Value creation

fundamental value/yr, % of market cap
Value created / year

Liquidity

Daily turnover (listing)
159.4 mln ZAR

Shares: connector/market_inputs

Trailing 12-month dividends

Dividend yield
–
Paid per share
–
Dividend history →

Forward dividends

No confirmed data

To dividends →

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in M USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueM USDOperating profitM USDD&AM USDEBITDAM USDNet profitM USDOperating CFM USDCapex + M&AM USDAssetsM USDEquityM USDROE (annualized)Net debtM USDSource
2026-06-30H2 2026 (6M)OK1083.3
y/y -21.9%
-64.4
y/y -120.2%
58.5
y/y -8.7%
-5.8
y/y -101.5%
71.5
y/y 137.8%
200.4-67.06613.3
y/y -13.5%
4909.0
y/y 2.8%
3.3%-26.2Link
2025-12-31H1 2026 (6M)OK990.0
y/y -1.5%
105.5
y/y -32.4%
55.4
y/y 8.2%
160.9
y/y -22.3%
85.3
y/y -36.5%
207.4-63.37737.8
y/y 7.0%
4900.1
y/y 8.8%
3.4%1651.1Link
2025-06-30H2 2025 (6M)OK1388.2
y/y 11.3%
318.5
y/y -14.0%
64.1
y/y 17.8%
382.7
y/y -9.9%
-188.9
y/y -271.4%
182.5-209.87642.0
y/y 0.1%
4774.0
y/y 2.5%
-1.3%1642.6Link
2024-12-31H1 2025 (6M)OK987.5
y/y -16.0%
153.3
y/y -21.3%
50.3
y/y -4.1%
203.6
y/y -17.6%
132.1
y/y 2.6%
99.9-65.27233.6
y/y -4.4%
4505.7
y/y -3.1%
5.7%1518.0Link
2024-06-30H2 2024 (6M)OK1268.2
y/y —
373.8
y/y —
55.4
y/y —
429.2
y/y —
112.5
y/y —
202.7-216.17635.4
y/y 7.7%
4659.4
y/y 2.3%
5.1%1291.5Link
2023-12-31H1 2024 (6M)OK1136.0
y/y —
188.1
y/y —
50.7
y/y —
238.8
y/y —
124.3
y/y —
132.1-81.87564.3
y/y —
4648.5
y/y —
5.5%1115.4Link
2023-06-30FY 2023 (12M)OK2302.8
y/y —
466.5
y/y —
101.1
y/y —
567.6
y/y —
295.7
y/y —
312.2-176.17090.7
y/y —
4553.6
y/y —
—961.4Link

Net debt structure (leases included, IFRS 16) 2026-06-30

Debt (loans, bonds and leases)951
− Cash & equivalents977
Net debt-26

Net debt / LTM EBITDA: -0.2x

Conversion to USD. Balance sheet: rate effective on 2026-06-30, fixing date unspecified. Flows: sampled average at each calculation period's bounds and monthly 15ths. Latest source row: 2026-01-01 — 2026-06-30. Source: Frankfurter historical request.

Revenue & EBITDA

RevenueEBITDA

Half-year values ($ mln)

-50005001 0001 5002023 H12023 H22024 H12024 H22025 H12025 H22026 H1

Year-over-year change

-150%-100%-50%0%50%2023 H12023 H22024 H12024 H22025 H12025 H22026 H1

Cash flow

Operating and investing cash flow (OCF + ICF) ($ mln)

-50005001 0001 5002 0002023 H12023 H22024 H12024 H22025 H12025 H22026 H1

Net debt / cash ($ mln)

-50005001 0001 5002 0002023 H12023 FY2024 H12024 FY2025 H12025 FY2026 H1

Profit and cash

Profit is cash-backed
In a typical year of 2022–2026 operating cash flow came to 1.24x of reported net profit; after capex, 0.43x. Loss years (2025) are left out of the ratio.
year20222023202420252026
cash flow / profit0.83x1.06x1.41x—2.60x
accruals, % of assets1.0%-0.2%-1.3%-4.6%-3.9%
Last twelve months (to 2026-06-30): 2.60x of profit came back as operating cash flow.
net debt / EBITDA -0.2x · capex 2.0x of depreciation
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Research & reviews

Our earnings breakdowns and investment notes on this issuer.

All research →

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -100.0%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30)
= (-6 − 383) × 2.00
-243
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (4 367 + -26) ÷ 155
28.0x
3. Target multiple
(Current EV/EBITDA + 8) ÷ 2
= (28.0 + 8) ÷ 2
18.0x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= 1 669 + 0 + 0 − 0
0
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (-243 × 18.0 + 0) ÷ 4 367
-100.0%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • half-year basis (semi-annual reporter)
  • dividends/buybacks not in data - balance cash flow uses net-debt change only
  • net-cash rise stripped: net debt fell while EBITDA declined and no share dilution measured (likely equity raise / recapitalisation)
  • EBITDA growth from 3-yr FY trend, min of avg & latest YoY (anomalous latest-period delta)
  • EBITDA-growth term clamped to ±market cap

Revenue growth & acceleration

Growth decelerating ▼
Last-year revenue growth -20% vs -3% the year before — a -16.6 pp move. 3-year CAGR -5%.
revenue growth by year: 2024 +10% · 2025 -3% · 2026 -20%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

Trailing 12 months

Dividend yield
–
Paid per share
–

Forward dividends

No confirmed data

Paid (completed)

DatePer shareDetailsStatusSource
2026-10-07232 ZAREx-dividend: 232 ZAR per sharePaidYahoo Finance (ex-div)
2025-10-01211 ZAREx-dividend: 211 ZAR per sharePaidYahoo Finance (ex-div)
2024-09-18359 ZAREx-dividend: 359 ZAR per sharePaidYahoo Finance (ex-div)
2023-09-20342 ZAREx-dividend: 342 ZAR per sharePaidYahoo Finance (ex-div)
2022-09-21326 ZAREx-dividend: 326 ZAR per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Investor reporting (IR): https://www.aspenpharma.com/investor-relations/

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Aspen Pharmacare (APN) — from primary filings.

Frequently asked questions

What is Aspen Pharmacare (APN)'s P/E ratio?
Aspen Pharmacare (APN) trades at a P/E of 27.8x (price to trailing 12-month earnings).
What is Aspen Pharmacare (APN)'s EV/EBITDA?
Aspen Pharmacare (APN) trades at 28.0x EV/EBITDA.
What is Aspen Pharmacare (APN)'s P/B ratio?
Aspen Pharmacare (APN) trades at a P/B of 0.9x.
What is Aspen Pharmacare (APN)'s dividend yield?
Aspen Pharmacare (APN)'s trailing 12-month dividend yield is 1.3%.
What is Aspen Pharmacare (APN)'s return on equity (ROE)?
Aspen Pharmacare (APN)'s ROE is 2.9%.
What is Aspen Pharmacare (APN)'s market capitalization?
Aspen Pharmacare (APN)'s market cap is 4.4 bn USD.

See also: South African Stocks (2026): Gold, Cheap Banks and the JSE Discount · The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map